This document is a publication of a patent application filed by Cellicure, Inc. for engineered immune cells, including chimeric antigen receptors (CARs) and methods of use. The application, identified as US20260083845A1, was published on March 26, 2026, with a filing date of September 22, 2023. The core innovation relates to enhancing the killing activities of engineered immune cells, such as NK cells, NKT cells, and T cells, for potential therapeutic applications, particularly in oncology.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments and intellectual property in the field of cell-based therapeutics. Companies operating in the pharmaceutical and biotechnology sectors, especially those involved in CAR T-cell or CAR NK-cell therapies, should monitor this application and related patents for competitive intelligence and potential licensing opportunities. No compliance actions are required at this stage.